Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (4): 587-590    DOI: 10.31083/j.ejgo.2020.04.5295
Original Research Previous articles | Next articles
Advanced stage ovarian cancer survival in Jakarta
Sigit Purbadi1, *(), Gregorius Tanamas1, Lisa Novianti1
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, 10430 Jakarta, Indonesia
Download:  PDF(198KB)  ( 234 ) Full text   ( 14 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: Ovarian cancer is one of most common cancers among women and has high mortality rate. In Indonesia, most patients initially present with advanced stage disease. Several factors contribute to ovarian cancer survival rate. Here, we evaluate factors that contributed to ovarian cancer survival rate in our medical center. Materials and Methods: This is a retrospective study reporting on 128 advanced stage ovarian cancer cases in Dr. Cipto Mangunkusumo Central General Hospital, a national reference and teaching hospital in Jakarta, Indonesia. Patients were treated with cytoreductive surgery and chemotherapy, and followed for a five-year period. Univariate and multivariate survival analyses were performed to investigate the impact of age, parity, residual tumor, chemotherapy regimen, and lymph nodal status on overall survival. Results: In 51.6% of patients, surgery failed to achieve optimal debulking. The overall two and four year post-diagnosis survival rates were 28.7% and 9.4%, respectively. Uni-variate analysis revealed patient age, stage, histopathology, residual tumor, chemotherapy administration, but not the regimen and treatment completeness, impact patient survival. Multivariate analysis showed cancer stage (HR = 1.3, p = 0.04), and chemotherapy (HR = 2.8, p = 0.01) affected survival rate. Conclusion: Advanced stage ovarian cancer has a poor survival rate, especially in older patients. In this study, the only factors that impacted patient survival were cancer stage and adjuvant chemotherapy. Complex cytoreductive surgery in advanced stage ovarian cancer should also be performed to improve patient survival.
Key words:  Advanced stage ovarian cancer      Survival rate      Residual tumor      Cytoreductive surgery      Chemotherapy      Histopathology     
Submitted:  19 June 2019      Accepted:  19 September 2019      Published:  15 August 2020     
*Corresponding Author(s):  SIGIT PURBADI     E-mail:  sigitpurbadi@gmail.com

Cite this article: 

Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.04.5295     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I4/587

[1] Joseph J. Noh, Sir-Yeon Hong, Byeong-gie Kim. Malignant perivascular epithelioid cell tumor (PEComa) of uterus: A case report with literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 495-499.
[2] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[3] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[4] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[5] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[6] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[7] X.F. Xu, Q. Li, A.Y. Dai, H.J. Zhou, J.X. Ling. Neoadjuvant chemotherapy followed by radical surgery for Stage IB2 cervical cancer in pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 489-491.
[8] A. Antar, H. AlJawad, A. AlMuslim, N. El-Majzoub. Isolated late recurrence of epithelial ovarian cancer in cervical lymph nodes[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1067-1069.
[9] Yangyang Shi, Yongyun Shi, Dabao Wu. A case of placental site trophoblastic tumor and a retrospective analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1096-1099.
[10] S. Dierckxsens, B. Geerinckx, M.T. Huizing, W.A.A. Tjalma. A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 714-721.
[11] H. Oikiri, M. Futagami, J. Watanabe, Y. Yokoyama. Adenocarcinoma of the cervix: its prognosis and difficult pathological diagnosis[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 728-733.
[12] S. Cierniak, R. Koktysz, M. Jesiotr, A. Gąsowska-Bodnar, L. Bodnar. Expression of the PI3K/AKT/mTOR pathway as a prognostic factor in patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 744-751.
[13] S. Rahatli, H. Akilli, N. Haberal, O. Altundag, A. Haberal, A. Ayhan. Surgical management and outcomes of metastatic tumors to the ovaries[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 820-824.
[14] X. Xu, L. Zheng, B. Xue, M. Yao, Y. Xu. Primary Burkitt lymphoma presenting as ovarian tumor rupture: a case report and literature review[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 862-866.
[15] S. Furukawa, K. Hasegawa, Y. Nozawa, Y. Endo, M. Takata, F. Yoshida-Saito, S. Nakamura, R. Yamauchi. A rare case of primary ovarian leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 870-874.
No Suggested Reading articles found!